What this Trial Is About

This research aims to compare the effectiveness of three glucocorticoid drugs—methylprednisolone, dexamethasone, and hydrocortisone—in treating patients with acute respiratory distress syndrome (ARDS). ARDS is a severe lung condition caused by various illnesses such as pneumonia and sepsis, leading to inflammation and breathing difficulties. The study explores how these medications impact the inflammatory processes triggered in ARDS, including the role of glucocorticoid receptors and critical illness-related corticosteroid insufficiency. Participants receive one of three treatments: methylprednisolone at 1 mg/kg/day (approximately 70 mg/day), dexamethasone at 13 mg/day, or hydrocortisone at 350 mg/day. The study compares these equivalent doses to evaluate their effects on ARDS. The treatments are given during the early phase of ARDS when inflammation is most active, as this is considered the critical period for glucocorticoid intervention. During the study, researchers monitor participants closely for 28 days to assess mortality after starting treatment. Participants must be receiving mechanical ventilation for hypoxemic respiratory failure and meet specific diagnostic criteria for ARDS. The study includes chest imaging, oxygen level monitoring, and assessments of respiratory symptoms. Researchers aim to understand which glucocorticoid provides the best response in reducing inflammation and improving survival in ARDS patients.

A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome